心脑血管疾病专栏

妊娠期高血压疾病产后血压管理:从指南分歧到数字化主动干预的整合视角

  • 杨绪辰 ,
  • 梅天茹 ,
  • 邵一菲 ,
  • 马珏 ,
  • 郑黎强
展开
  • 1.上海交通大学公共卫生学院妇女儿童健康系 (上海 200025 )
    2.中国医科大学公共卫生学院流行病学教研室 (辽宁 沈阳 110122 )
    3.上海交通大学医学院附属国际和平妇幼保健院临床研究中心 (上海 200030 )
郑黎强,教授、博士研究生导师,现任上海交通大学医学院附属国际和平妇幼保健院临床研究中心主任,教育部环境与儿童健康重点实验室兼职PI。于中国医科大学获公共卫生与预防医学博士学位,曾赴美国杜兰大学流行病学系访学。主要研究方向为围产流行病学、慢性病流行病学与临床研究方法学。主持国家自然科学基金面上项目、青年项目等多项国家级课题,以第一作者或通信作者发表SCI论文65篇,研究成果发表于《Hypertension》、《JAMA Netw Open》、《Nutrients》等国际权威期刊。曾荣获国家科学技术进步二等奖、中华医学科技奖。担任多本SCI杂志特约审稿人及国内核心期刊编委,《Nutrients》杂志客座编辑。

收稿日期: 2026-05-09

  修回日期: 2026-06-10

  录用日期: 2026-06-15

  网络出版日期: 2026-08-13

基金资助

国家重点研发计划项目(2023YFC2705501);上海市公共卫生研究专项项目(2025GKM25);上海交通大学内蒙古研究院科技创新发展专项项目(2025XYJG0001-01-19)

Postpartum blood pressure management of hypertensive disorders in pregnancy : An integrated perspective from guideline discrepancies to digital proactive interventions

  • Xuchen YANG ,
  • Tianru MEI ,
  • Yifei SHAO ,
  • Jue MA ,
  • Liqiang ZHENG
Expand
  • 1.Department of Women and Children′s Health,School of Public Health,Shanghai Jiao Tong University,Shanghai 200025,Shanghai,China
    2.Department of Epidemiology,School of Public Health,China Medical University,Shenyang 110122,Liaoning,China
    3.Clinical Research Center of Shanghai Jiao Tong University School of Medicine,International Peace Maternity and Child Health Hospital,Shanghai 200030,Shanghai,China

Received date: 2026-05-09

  Revised date: 2026-06-10

  Accepted date: 2026-06-15

  Online published: 2026-08-13

摘要

妊娠是评估女性心血管疾病(CVD)风险的理想切入点。妊娠期高血压疾病(hypertensive disorders in pregnancy, HDP)作为妊娠期常见并发症,使产妇远期罹患CVD的风险显著升高,因此产后血压管理成为衔接女性长期心血管健康的关键环节。然而HDP患者产后血压的管理与随访面临核心挑战:一是指南缺乏共识,国内外启动降压治疗的阈值差异显著;二是传统随访模式低效,导致风险筛查错失良机。近年来研究显示,更严格的产后血压控制可能带来更多心血管收益,相关随机对照试验正在探索最优控制目标。管理模式也向主动化、数字化转型,以家庭血压监测(home BP monitoring, HBPM)+远程药物调整为核心的干预,可显著改善血压控制效果。未来需通过高质量长期临床试验明确不同亚型HDP的适宜控制目标,探索HBPM整合模式的可行性与成本效益。HDP产后血压管理应纳入女性终身心血管预防体系,减少短期妊娠并发症风险与远期心血管负担。

本文引用格式

杨绪辰 , 梅天茹 , 邵一菲 , 马珏 , 郑黎强 . 妊娠期高血压疾病产后血压管理:从指南分歧到数字化主动干预的整合视角[J]. 实用医学杂志, 2026 , 42(15) : 2675 -2683 . DOI: 10.3969/j.issn.1006-5725.2026.15.001

Abstract

Pregnancy serves as an ideal entry-point for assessing women's risk of cardiovascular disease. Hypertensive disorders in pregnancy (HDP), which are common complications during pregnancy, substantially elevate the risk of long-term cardiovascular disease in puerperae. As a result, postpartum blood pressure management has emerged as a crucial link for ensuring women's long-term cardiovascular health. Nevertheless, the management and follow-up of postpartum blood pressure in HDP patients encounter core challenges. Firstly, there is a lack of consensus among guidelines, with notable disparities in the thresholds for initiating antihypertensive treatment both at home and abroad. Secondly, the traditional follow-up model is inefficient, causing missed opportunities for risk screening. Recent research has indicated that more stringent postpartum blood pressure control may yield greater cardiovascular benefits, and relevant randomized controlled trials are currently exploring the optimal control target. The management model is also undergoing an active and digital transformation. Interventions centered on home BP monitoring (HBPM) combined with remote medication adjustment can significantly enhance blood pressure control outcomes. In the future, high-quality long-term clinical trials are required to determine the appropriate control targets for different HDP subtypes and to explore the feasibility and cost-effectiveness of integrated HBPM models. Postpartum blood pressure management for HDP should be integrated into the long-term cardiovascular prevention system for women to mitigate the risk of short-term pregnancy complications and long-term cardiovascular burden.

参考文献

[1] MANIECKA-BRY?A I, PIKALA M, BRY?A M. Life years lost due to cardiovascular diseases[J]. Kardiol Pol, 2013, 71(10): 1065-1072. doi:10.5603/kp.2013.0262 .
[2] VOGEL B, ACEVEDO M, APPELMAN Y, et al. The Lancet women and cardiovascular disease Commission: Reducing the global burden by 2030[J]. Lancet, 2021, 397(10292): 2385-2438. doi:10.1016/S0140-6736(21)00684-X .
[3] STAFF A C, REDMAN C W G, WILLIAMS D, et al. Pregnancy and long-term maternal cardiovascular health: Progress through harmonization of research cohorts and biobanks[J]. Hypertension, 2016, 67(2): 251-260. doi:10.1161/hypertensionaha. 115.06357 .
[4] COUNTOURIS M, MAHMOUD Z, COHEN J B, et al. Hypertension in pregnancy and postpartum: Current standards and opportunities to improve care[J]. Circulation, 2025, 151(7): 490-507. doi:10.1161/circulationaha.124.073302 .
[5] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 妊娠期高血压疾病心血管风险综合管理专家共识[J]. 中华心血管病杂志, 2025, 53(3):235-246. doi: 10.3760/cma.j.cn112148-20241024-00643 .
[6] DALL’ASTA A, D’ANTONIO F, SACCONE G, et al. Cardiovascular events following pregnancy complicated by pre-eclampsia with emphasis on comparison between early- and late-onset forms: Systematic review and meta-analysis[J]. Ultrasound Obstet Gynecol, 2021, 57(5): 698-709. doi:10.1002/uog. 22107 .
[7] MESA A, PUIG-JOVé C, PANé A, et al. Preeclampsia as an independent predictor of atherosclerosis progression in women with type 1 diabetes: A 5-year prospective study[J]. Cardiovasc Diabetol, 2025, 24(1): 160. doi:10.1186/s12933-025-02719-3 .
[8] KEITAANP?? N, TYRMI J S, TOIVONEN E, et al. Impact of preeclampsia duration on long-term cardiovascular disease risk[J]. Hypertension, 2026, 83(2): e25054. doi:10.1161/HYPERTENSIONAHA.125.25054 .
[9] DAVIDSON B, RAYNER B, WEARNE N, et al. Long-term cardio-renal-metabolic complications following pre-eclampsia[J]. Cardiol Clin, 2025, 43(3): 457-467. doi:10.1016/j.ccl.2024. 12.005 .
[10] JANSSEN E B N J, GHOSSEIN-DOHA C, HOOIJSCHUUR M C E, et al. Hypertension and cardiometabolic disorders appear 5-10 years earlier in women with pre-eclampsia[J]. Eur J Prev Cardiol, 2025, 32(10): 822-832. doi:10.1093/eurjpc/zwaf187 .
[11] SHIH Y H, YANG C Y, LUNG C C. Long-term risk of diabetes following hypertensive disorders of pregnancy: A retrospective cohort study[J]. World J Diabetes, 2025, 16(6): 1050-1058. doi:10.4239/wjd.v16.i6.105080 .
[12] JANSEN G, DE ROOY A, JANSSEN E, et al. Atherosclerosis after pre-eclampsia: Systematic review and meta-analysis[J]. Ultrasound Obstet Gynecol, 2026, 67(1): 15-26. doi:10.1002/uog. 70014 .
[13] YAO J V, WANG B, GANES A, et al. Subclinical atherosclerosis in women after pre-eclampsia: A systematic review and meta-analysis[J]. Heart, 2026, 112(9): 473-479. doi:10.1136/heartjnl-2024-325493 .
[14] BELLO N, RENDON I S H, ARANY Z. The relationship between pre-eclampsia and peripartum cardiomyopathy a systematic review and meta-analysis[J]. J Am Coll Cardiol, 2013, 62(18): 1715-1723. doi:10.1016/j.jacc.2013.08.717 .
[15] TOO G, WEN T, BOEHME A K, et al. Timing and risk factors of postpartum stroke[J]. Obstet Gynecol, 2018, 131(1): 70-78. doi:10.1097/aog.0000000000002372 .
[16] PETERSEN E E, DAVIS N L, GOODMAN D, et al. Vital signs: pregnancy-related deaths, United States, 2011–2015, and strategies for prevention, 13 states, 2013–2017[J]. MMWR Morb Mortal Wkly Rep, 2019, 68(18):423-429. doi:10.15585/mmwr.mm6818e1 .
[17] BUSHNELL C, KERNAN W N, SHARRIEF A Z, et al. 2024 guideline for the primary prevention of stroke: A guideline from the American heart association/American stroke association[J]. Stroke, 2024, 55(12):e344-e424. doi:10.1161/str. 0000000000000475 .
[18] BARRY M J, NICHOLSON W K, SILVERSTEIN M, et al. Screening for hypertensive disorders of pregnancy: US preventive services task force final recommendation statement[J]. Jama, 2023, 330(11): 1074. doi:10.1001/jama.2023.16991 .
[19] LI Q, WU T, MAO Y, et al. Complications in hospitalized neonates born to mothers with HDP subtypes: A retrospective cohort study and mediation analysis[J]. BMC Pregnancy Childbirth, 2025, 25(1): 668. doi:10.1186/s12884-025-07778-8 .
[20] 刘俊, 田福林, 陈琳, 等. 妊娠早期正常高值血压和1级高血压与孕产妇子痫前期及妊娠不良结局的关系[J]. 实用医学杂志, 2025, 41(10): 1555-1562. doi: 10.3969/j.issn.1006-5725. 2025.10.018 .
[21] MUKHTAROVA N, HETZEL S J, JOHNSON H M, et al. Longitudinal blood pressure patterns of women with hypertensive disorders of pregnancy: Preconception through postpartum[J]. J Matern Fetal Neonatal Med, 2022, 35(25): 9023-9030. doi:10.1080/14767058.2021.2012650 .
[22] LOPES PERDIGAO J, HIRSHBERG A, KOELPER N, et al. Postpartum blood pressure trends are impacted by race and BMI[J]. Pregnancy Hypertens, 2020, 20: 14-18. doi:10.1016/j.preghy.2020.02.006 .
[23] PARKER S E, AJAYI A, YARRINGTON C D. De novo postpartum hypertension: Incidence and risk factors at a safety-net hospital[J]. Hypertension, 2023, 80(2): 279-287. doi:10.1161/HYPERTENSIONAHA.122.19275 .
[24] 中华医学会妇产科学分会妊娠期高血压疾病学组. 妊娠期高血压疾病诊治指南(2020)[J]. 中华妇产科杂志, 2020, 55(4): 227-238. doi:10.3760/cma.j.cn112141-20200114-00039 .
[25] KITT J, FOX R, FROST A, et al. Long-term blood pressure control after hypertensive pregnancy following physician-optimized self-management: The POP-HT randomized clinical trial[J]. Jama, 2023, 330(20): 1991. doi:10.1001/jama.2023.21523 .
[26] CAIRNS A E, TUCKER K L, LEESON P, et al. Self-management of postnatal hypertension: The SNAP-HT trial[J]. Hypertension, 2018, 72(2): 425-432. doi:10.1161/hypertensionaha.118.10911 .
[27] BEHRENS I, BASIT S, MELBYE M, et al. Risk of post-pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: Nationwide cohort study[J]. Bmj, 2017: j3078. doi:10.1136/bmj.j3078 .
[28] URRUTIA R P, LOOP M S, JOHNSON J D, et al. Blood pressure 15 to 90 days after a hypertensive disorder of pregnancy and later hypertension[J]. Hypertension, 2026, 83(2)::e24393. doi:10.1161/hypertensionaha.124.24393 .
[29] LEWEY J, SHEEHAN M, BELLO N A, et al. Cardiovascular risk factor management after hypertensive disorders of pregnancy[J]. Obstet Gynecol, 2024, 144(3): 346-357. doi:10.1097/aog.0000000000005672 .
[30] MPOFU J J, ROBBINS C L, GARLOW E, et al. Surveillance of hypertension among women of reproductive age: A review of existing data sources and opportunities for surveillance before, during, and after pregnancy[J]. J Women’s Health, 2021, 30(4): 466-471. doi:10.1089/jwh.2020.8977 .
[31] 中国高血压防治指南修订委员会, 高血压联盟(中国, 中国医疗保健国际交流促进会高血压分会, 等. 中国高血压防治指南(2024年修订版)[J]. 中华高血压杂志, 2024, 32(7): 603-700. doi:10.16439/j.issn.1673-7245.2024.07.002 .
[32] National Institute for Health and Care Excellence. Hypertension in pregnancy: Diagnosis and management [EB/OL].(2025-11-24)[2026-06-01]. . doi:10.1017/cbo9781316227633.040
[33] Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222[J]. Obstet Gynecol, 2020, 135 6:e237-e260. doi:10.1097/AOG.0000000000003891 .
[34] MAGEE L A, BROWN M A, HALL D R, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice[J]. Pregnancy Hypertens, 2022, 27: 148-169. doi:10.1016/j.preghy.2021.09.008 .
[35] MAGEE L A, SMITH G N, BLOCH C, et al. Guideline No. 426: Hypertensive disorders of pregnancy: Diagnosis, prediction, prevention, and management[J]. J Obstet Gynaecol Can, 2022, 44(5): 547-571.e1. doi:10.1016/j.jogc.2022.03.002 .
[36] POON L C, NGUYEN-HOANG L, SMITH G N, et al. Hypertensive disorders of pregnancy and long-term cardiovascular health: FIGO Best Practice Advice[J]. Int J Gynecol Obstet, 2023, 160(S1): 22-34. doi:10.1002/ijgo.14540 .
[37] Society of Obstetric Medicine in Australia and New Zealand. SOMANZ hypertension in pregnancy guideline 2023[EB/OL].(2025-11-24)[2026-06-01]. .
[38] LEWEY J, BECKIE T M, BROWN H L, et al. Opportunities in the postpartum period to reduce cardiovascular disease risk after adverse pregnancy outcomes: A scientific statement from the American heart association[J]. Circulation, 2024, 149(7): :e330-e346. doi:10.1161/cir.0000000000001212 .
[39] JONES D W, FERDINAND K C, TALER S J, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines[J]. JACC, 2025, 86(18): 1567-1678. doi:10.1016/j.jacc.2025.05.007 .
[40] WHELTON P K, CAREY R M, ARONOW W S, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults a report of the American college of cardiology/American heart association task force on clinical practice guidelines[J]. J Am Coll Cardiol, 2018, 71(19): e127-e248. doi:10.1016/j.jacc.2017.11.006 .
[41] ROSENFELD E B, SAGARAM D, LEE R, et al. Management of postpartum preeclampsia and hypertensive disorders (MOPP) postpartum tight vs standard blood pressure control[J]. JACC Adv, 2025, 4(3): 101617. doi:10.1016/j.jacadv.2025.101617 .
[42] LUMSDEN R, PAGE C B, PHELAN M, et al. Longitudinal management of cardiovascular risk factors among postpartum women[J]. J Womens Health (Larchmt), 2024, 33(7): 853-862. doi:10.1089/jwh.2023.0461 .
[43] VAUGHT A J, MINHAS A, BOYER T, et al. Incidence of essential hypertension but not echocardiographic abnormalities at four years with a history of preeclampsia with severe features[J]. Pregnancy Hypertens, 2021, 25: 185-190. doi:10.1016/j.preghy. 2021.06.008 .
[44] BHAT S, ELMAN D, PYAKUREL A, et al. The prevalence of documented cardiovascular-related pregnancy complications: Cross-sectional study in an academic primary care centre[J]. BJGP Open, 2022, 6(4): BJGPO.2022.0070. doi:10.3399/bjgpo.2022.0070 .
[45] PALATNIK A, SUNJI N, PETERSON Z, et al. Intensive postpartum antihypertensive treatment (IPAT) and healthy lifestyle education: Study protocol for a pilot randomized controlled trial for patients with hypertensive disorders of pregnancy[J]. Contemp Clin Trials, 2024, 147: 107710. doi:10.1016/j.cct.2024.107710 .
[46] HAUSPURG A. Optimal Blood Pressure Treatment Thresholds Postpartum[EB/OL]. (2026-06-02)[2026-06-26]. .
[47] FAHEY J. Enhancing Care & Outcomes for Patients During the First Postpartum Year[EB/OL]. (2026-04-01)[2026-06-26]. .
[48] KITT J, KRASNER S, BARR L, et al. Cardiac remodeling after hypertensive pregnancy following physician-optimized blood pressure self-management: The POP-HT randomized clinical trial imaging substudy[J]. Circulation, 2024, 149(7): 529-541. doi:10.1161/circulationaha.123.067597 .
[49] GILL E, JIN X, FERNANDEZ C, et al. Association of hypertension disorders of pregnancy and left ventricular remodeling after 15?years follow-up: Findings from the Bogalusa Heart Study[J]. J Hypertens, 2026, 44(3): 399-406. doi:10.1097/hjh. 0000000000004216 .
[50] HAUSPURG A, COUNTOURIS M E, CATOV J M. Hypertensive disorders of pregnancy and future maternal health: How can the evidence guide postpartum management?[J]. Curr Hypertens Rep, 2019, 21(12): 96. doi:10.1007/s11906-019-0999-7 .
[51] KWAK S, PARK C S, PARK Y, et al. Hypertensive disorders of pregnancy subtypes and long-term cardiovascular risk[J]. JAMA Intern Med, 2026, 186(4): 469-478. doi:10.1001/jamainternmed.2025.7802 .
[52] COHEN J L, DAW J R. Postpartum cliffs—Missed opportunities to promote maternal health in the United States[J]. JAMA Health Forum, 2021, 2(12): e214164. doi:10.1001/jamahealthforum. 2021.4164 .
[53] LI J, ZHOU Q, WANG Y, et al. Risk factors associated with attendance at postpartum blood pressure follow-up visit in discharged patients with hypertensive disorders of pregnancy[J]. BMC Pregnancy Childbirth, 2023, 23(1): 485. doi:10.1186/s12884-023-05780-6 .
[54] LEWEY J, LEVINE L D, YANG L, et al. Patterns of postpartum ambulatory care follow-up care among women with hypertensive disorders of pregnancy[J]. J Am Heart Assoc, 2020, 9(17): e016357. doi:10.1161/jaha.120.016357 .
[55] FOREMAN M A, ROSS A, BURGESS A P H, et al. Barriers and facilitators of digital health use for self-management of hypertensive disorders by black pregnant women [J]. AMIA Annu Symp Proc, 2025,2024:433-442. doi: 10.1007/s10564-025-01264-x .
[56] REILINGH A Y A M, BURGER R J, BACHIRI S EL, et al. Cardiovascular risk management after hypertensive disorders and diabetes during pregnancy, in a multi-ethnic population: A qualitative study among women and healthcare providers[J]. Pregnancy Hypertens, 2025, 39: 101203. doi:10.1016/j.preghy.2025. 101203 .
[57] MATTOCKS K M, SHENETTE L L, GOLDSTEIN K, et al. Understanding pregnancy-related cardiovascular disease risk communication and management among women veterans[J]. J Womens Health (Larchmt), 2025,34(3):e433-e440. doi:10.1089/jwh.2024.0618 .
[58] MEO M L N, KATUUK M E, KRISTAMULIANA K. Uncertainty in knowledge and care: Pregnant women′s experiences with hypertensive disorders of pregnancy in eastern Indonesia—a qualitative study[J]. Aust N Z J Obstet Gynaecol, 2026, 66(2): e70118. doi:10.1111/ajo.70118 .
[59] BALAKUMARAN S, FISK? B S, SUGULLE M, et al. Hypertensive disorders of pregnancy: The use of eHealth technologies in postpartum follow-up strategies to reduce cardiovascular risk-A scoping review[J]. Health Inform J, 2026, 32: 14604582261421669. doi:10.1177/14604582261421669 .
[60] SANGHAVI M, PACKARD E, SPERLING S, et al. Telemedicine may increase visit completion rates in postpartum patients with preeclampsia[J]. PLoS One, 2022, 17(10): e0275741. doi:10.1371/journal.pone.0275741 .
[61] SOCRATES T, WENKER C, VISCHER A, et al. Characteristics of the Basel postpartum hypertension cohort (Basel-PPHT cohort): An interim analysis[J]. Diagnostics (Basel), 2024, 14(13): 1347. doi:10.3390/diagnostics14131347 .
[62] UNLU O, ZELLE D, CANNON C P, et al. Patient engagement with home blood pressure monitoring[J]. JAMA Cardiol, 2026, 11(3): 288. doi:10.1001/jamacardio.2025.5196 .
[63] 魏明珍. 多模式护理在妊娠期高血压患者术后长期血压管理中的作用研究[J]. 心血管病防治知识, 2021, 11(27): 60-62. doi: 10.3969/j.issn.1672-3015(x).2021.27.020 .
[64] 赵志新, 王瑞霞, 侯志飞, 等. 互联网+微信群组健康教育对HDP患者产后自我管理能力及血压控制效果[J]. 中国计划生育学杂志, 2024, 32(3): 595-599. doi:10.3969/j.issn.1004-8189.2024.03.022 .
[65] NERENBERG K A, COOKE C L, SMITH G N, et al. Optimising women’s cardiovascular health after hypertensive disorders of pregnancy: A translational approach to cardiovascular disease prevention[J]. Can J Cardiol, 2021, 37(12): 2056-2066. doi:10.1016/j.cjca.2021.08.007 .
[66] SLATER K, TAYLOR R, MCLAUGHLIN K, et al. Co-designing an intervention for cardiovascular disease risk assessment and management after hypertensive disorders of pregnancy in primary care[J]. Health Res Policy Syst, 2025, 23(1): 23. doi:10.1186/s12961-024-01269-6 .
[67] BURGESS A, STOVER S. Improving cardiovascular follow-up after diagnosis of a hypertensive disorder of pregnancy using the electronic health record[J]. MCN Am J Matern Child Nurs, 2023, 48(3): 127-133. doi:10.1097/NMC.0000000000000911 .
[68] CLAPP M A, RAY A, LIANG P, et al. Postpartum primary care engagement using default scheduling and tailored messaging: A randomized clinical trial[J]. JAMA Netw Open, 2024, 7(7): e2422500. doi:10.1001/jamanetworkopen.2024.22500 .
[69] VARZIDEH F, MONE P, KANSAKAR U, et al. Artificial intelligence in cardiovascular medicine: Focus on hypertension[J]. Hypertension, 2026, 83(6): e26094. doi:10.1161/HYPERTENSIONAHA.126.26094 .
[70] WANG Y, TAN W, CHENG S, et al. Large language model agent for managing patients with suspected hypertension[J]. Hypertension, 2026, 83(1): 212-224. doi:10.1161/HYPERTENSIONAHA.125.25305 .
[71] NING Y, ONG J C L, CHENG H, et al. How can artificial intelligence transform the training of medical students and physicians?[J]. Lancet Digit Health, 2025, 7(10): 100900. doi:10.1016/j.landig.2025.100900 .
[72] ZAND J, MIAO J, HOMMOS M S, et al. Performance of large language models in analyzing common hypertension scenarios[J]. Hypertension, 2026, 83(1): 225-234. doi:10.1161/hypertensionaha.125.25492 .
[73] WANG Y, LUAN Y, CHENG S, et al. A multi-layer retrieval-augmented large language model framework for enhancing hypertension education[J]. Hypertens Res, 2026, 49(4): 1428-1440. doi:10.1038/s41440-025-02481-9 .
[74] YANG H, FAN C, LIU C. Development and validation of a machine learning model to predict comorbid hypertension in patients with type 2 diabetes[J]. Front Med(Lausanne), 2026, 13: 1754916. doi:10.3389/fmed.2026.1754916 .
[75] GUIMBAUD J B, CALABRE E, DE CID R, et al. An informed machine learning based environmental risk score for hypertension in European adults[J]. Artif Intell Med, 2025, 165: 103139. doi:10.1016/j.artmed.2025.103139 .
[76] KARNIK A, YANG E. Artificial intelligence to improve blood pressure control: A state-of-the-art review[J]. Am J Hypertens, 2025, 38(8): 519-526. doi:10.1093/ajh/hpaf035 .
[77] MO?LL B, SAND ARONSSON F. Harm reduction strategies for thoughtful use of large language models in the medical domain: Perspectives for patients and clinicians[J]. J Med Internet Res, 2025, 27: e75849. doi:10.2196/75849 .
[78] MENNELLA C, MANISCALCO U, DE PIETRO G, et al. Ethical and regulatory challenges of AI technologies in healthcare: A narrative review[J]. Heliyon, 2024, 10(4): e26297. doi:10.1016/j.heliyon.2024.e26297 .
[79] CARVALHO E, MASCARENHAS M, PINHEIRO F, et al. Predetermined change control plans: Guiding principles for advancing safe, effective, and high-quality AI-ML technologies[J]. JMIR AI, 2025, 4: e76854. doi:10.2196/76854 .
文章导航

/